Tango Therapeutics' Executive Chair Barbara Weber departs, separation agreement filed

Tango Therapeutics, Inc. disclosed that Dr. Barbara Weber's employment with the company as its Executive Chair ended on August 3, 2026, in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026.¹ Under that agreement, Weber's departure also triggered her resignation from all other officer and board positions, including her seat on the company's board of directors.¹ Tango said Weber's exit did not stem from any dispute with the company over its operations, practices or policies.¹

The company originally disclosed the departure in a Form 8-K filed August 6, 2026, and followed with a Form 8-K/A on August 7 to add the finalized terms of the separation agreement, which Weber and the company executed on August 6, 2026.

Under the executed agreement, Weber will receive severance pay at her current base salary through December 31, 2026, paid in substantially equal installments, plus reimbursement for monthly COBRA premiums through the same date.² The agreement also provides for full acceleration of her outstanding option and restricted stock unit awards, subject to Compensation Committee approval; an extension of the post-termination exercise period for her vested options to the earlier of August 3, 2027 or the original expiration date; and a pro-rata 2026 annual incentive payment, to be paid alongside other employees' incentive payments no later than March 15, 2027.² These benefits are contingent on Weber not revoking the agreement, as specified in her employment contract.

Tango President and CEO Dr. Malte Peters commented on the departure, and Weber offered remarks on the company's progress in the accompanying press release, but the filings did not name a successor for the Executive Chair role.